vertex pharmaceuticals journavx - Search News

Vertex Pharmaceuticals Shares Gain

Hosted on MSN · 46m

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

Business Insider · 1h

Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence

The Wall Street Journal on MSN · 12h

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

1h

Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results